October 26-28, 2021 | Digital Event

www.neo-antigen.com

Book before October 26 to save up to $100

6th Annual

Neoantigen Based Therapies Summit

Weaponizing Vaccine and Cell Based Immunotherapies



Accelerate the Selection, Identification, & Validation of Personalized & Shared Neoantigens to Create Meaningful T Cell Responses

Expert Speakers Include:

Mathias Vormehr
Director Cancer Vaccines
BioNTech SE

Karin Jooss
Head of R&D
Gritstone Bio

Christopher Gallen
CEO
Treos Bio

Joann Peters
VP Clinical & Business Operations
Geneos Therapeutics

Andreas Gutierrez
Executive Vice President & Chief Medical Officer
Advaxis Inc

Paul Higham
CEO
Valo Therapeutics

Proud to Partner With:

NEC NEC OncoImmunity AS
PolyPeptide GROUP
Cayman CHEMICAL
Personalis
ALMAC
cytiva
GYROS PROTEIN Technologies
CEM We Simplify Science
PEPSCAN Shaping peptides to perfection
CellCarta formerly Caprion-HistoGeneX
CPC scientific Peptide Partners. Concept to Commercial.
L7INFORMATICS
vivitide Science for life

+1 415 735 3289 info@hansonwade.com
www.neo-antigen.com Neoantigens in Immunotherapy
hansonwade

Welcome to the 6th Neoantigen Based Therapies Summit

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies
Virtual Event

Your comprehensive end-to-end guide to transforming the clinical development of cell and vaccine based neoantigen therapies

The growth and comeback of the neoantigen space has resulted in an abundance of new data, innovative insights and valuable lessons learned on how to drive meaningful clinical responses, all of which will be shared at the **6th Neoantigen Based Therapies US Summit.**

Exploring the potential of shared neoantigens vs. personalized neoantigens and optimizing the selection and identification of the best and most immunogenic neoantigens, the world's leaders from the likes for **BioNTech, Gritstone, Advaxis, Genocea, Treos Bio** and many more will gather at the only 3-day summit focused on the exploding field of Neoantigen based Therapies.

Join over 100 experts to discuss what the **optimal control, clinical and combination trial designs** should look like, **advances in accurate and robust validation assays**, and explore how we can **manufacture effectively and at scale** both shared and personalized neoantigen based therapies.

Leave this meeting equipped with new collaborations across pharma, biotech and academia, and learn how to supercharge vaccine and cell immunotherapies for solid tumors and beyond.

What previous attendees have had to say:

"Terrific meeting featuring the latest advancement in the field of neoantigen directed approaches in tackling cancer, from both more mature as well as nascent programs"

Amphivena Therapeutics

"An excellent summary of the cutting edge development in cancer neoantigen-based research and therapies"

University of California

Your Checklist to Developing Safe & Effective Neoantigen Therapies

Maximize identification of novel meaningful neoantigens and neoepitopes to induce stronger anti-tumor immune responses with **Valo Therapeutics, Evaxion Biotech** and **Icahn School of Medicine at Mount Sinai**

Overcome tumor resistance mechanisms by harnessing the power of novel neoantigen sources with **Medigene, Frame Cancer Therapeutics, Genocea** and **GreyWolf Therapeutics**



Explore the latest clinical trial case studies to show safety, immunogenicity and efficacy of personalized neoantigen vaccines with **Gritstone Bio, Geneos Therapeutics** and **Treos Bio**

Harness the power of shared neoantigens to accelerate clinical development of off-the-shelf neoantigen immunotherapy with **Advaxis, PDC Line Pharma, Gritstone Bio** and **University of Miami**

Enhance clinical efficacy through establishing an adjuvant approach with **Immuniucm** and **BioNTech** and review applications of vaccine platforms beyond oncology with **Valo Therapeutics** and **Vaccibody**

+1 415 735 3289 info@hansonwade.com
www.neo-antigen.com Neoantigens in Immunotherapy
hansonwade

Your Expert Speakers

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies

Virtual Event

Hans-Peter Gerber
CSO
3T Biosciences

Andres Gutierrez
Executive Vice President, CMO
Advaxis Inc

Mathias Vormehr
Director Cancer Vaccines
BioNTech SE

Jens Kringelum
Director Genomic Immuno-Oncology
Evaxion Biotech

Ronald Plasterk
Founder, CEO
Frame Cancer Therapeutics

Chip Clark
CEO
Genocea Biosciences

Jessica Baker Flechtner
CSO
Genocea Biosciences

Hubert Lam
Senior Director
Genocea Biosciences

Joann Peters
VP Clinical & Business Operations
Geneos Therapeutics

Niranjan Sardesai
President & CEO, Founder
Geneos Therapeutics

Peter Joyce
CEO
Grey Wolf Therapeutics

Andrew Allen
CEO
Gritstone Bio

Karin Jooss
Head of R&D
Gritstone Bio

Julia Kodysh
Senior Scientist, Computational Research
Icahn School of Medicine, Mount Sinai

Alex Karlsson-Parra
CEO
Immunicum AB

Stephen Schoenberger
Professor
La Jolla Institute for Immunology

Dolores J. Schendel
CEO & CSO
Medigene AG

Elisa Scarselli
Co-Founder, CSO
Nouscom

Eric Halioua
President & CEO
PDC*line Pharma

Philip M Arlen
President & CEO
Precision Biologics, Inc

Massimo Fantini
Senior Scientist
Precision Biologics, Inc.

Christopher Gallen
Chairman & CEO
Treos Bio Ltd

Eli Gilboa
Professor of Immunology & Microbiology
University of Miami

Agnete Fredriksen
Chief Innovation & Strategy Officer
Vaccibody As

Paul Higham
CEO
Valo Therapeutics

Sari Pesonen
Head R&D
Valo Therapeutics

VAXIMM

Albrecht Meichle
VP Regulatory Affairs & CMC
Vaximm

Heinz Lubenau
CEO & Co-Founder
Vaximm

Christelle Johnson
Senior Field Applications Scientist, Cancer Genomics & Immuno-Oncology
Personalis

Wendy Hartsock
Director of Scientific Acceleratio
CEM

+1 415 735 3289 info@hansonwade.com
www.neo-antigen.com Neoantigens in Immunotherapy

hansonwade

Pre Conference Workshops

Tuesday October 26, 2021

9.30 - 15.30 EST | 6.30 - 12.30 PST

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies

Virtual Event

Workshop A

9.30am- 12pm

Natural NeoAgs: Hiding in Plain Sight

There are a variety of different modalities used to identify the best neoantigen candidates as targets for anti-tumor treatments, as it is a critical step in determining the clinical success of these cancer immunotherapies. We have developed a workflow that combines bioinformatic analysis with functional immunology to identify neoantigens through the T cell responses they induce, and find that nearly all cancer patients contain these in their peripheral repertoire.

This workshop will cover:

- Neoantigens can be functionally identified in nearly all cancer patients, regardless of TMB or histology
- Identified targets include shared driver mutations

Workshop Leader

Stephen Schoenberger
Professor
La Jolla Institute for Immunology

Workshop B

1pm-3.30pm

Vaccination Against Shared Neoantigens Induced in Recurrent & Future Tumors & Stability Tests to Monitor the Shelf Life of Monoclonal Antibodies Employed in Cancer Immunotherapy

To overcome the limitations of targeting random mutation-generated neoantigens, their inter- and intra-patient heterogeneity and paucity in most cancer patients, we are developing a novel vaccination concept whereby tumor cells are "marked" for vaccination by experimentally inducing (neo)antigens in the tumor cells in situ.

This workshop will explore:

- A common set of neoantigens that are induced in disseminated tumor lesions by tumor targeted siRNA mediated inhibition of the peptide transporter TAP.
- Vaccination against TAP downregulation induced neoantigens, by targeted inhibition of TAP in resident dendritic cells Inhibited tumor growth in transplantable and autochthonous murine tumor models that was superior to vaccination against mutation-derived neoantigens, and was devoid of measurable toxicity.
- Vaccination against induced antigens using one or two broadly applicable chemically synthesized oligonucleotides will also benefit the majority of patients that do not express or express too few mutation-derived neoantigens.

Stability tests performed to evaluate the integrity of the drug (such as PH, osmolarity, HPLC), the stability of the molecule over the time (such as integrity of heavy chain or light chain of the monoclonal antibody), the sterility of the bottle (such as endotoxin test, appearance of the solution)

Tests performed to evaluate the maintenance of the binding of monoclonal antibodies to their target antigens (ELISA) and to evaluate the stability of the activity of monoclonal antibodies against tumor cells (ADCC assay).

Workshop Leader

Eli Gilboa
Professor of Immunology & Microbiology
University of Miami

Massimo Fantini
Senior Scientist
Precision Biologics, Inc.

Conference Day One

Wednesday October 27, 2021

8.00 - 18.00 EST | 5.00 - 15.00 PST

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies
Virtual Event

WELCOME | SPEAKERS | AGENDA | PARTNER WITH US | REGISTER YOUR PLACE

	8.00 | 5.00	**Online Registration & Virtual Coffee**
 **Christopher Gallen** Chairman and CEO **Treos Bio Ltd**	**8.15 | 5.15**	**Chair's Opening Remarks**
Identifying the Most Meaningful Neoantigens to Accelerate Successful Clinical Development		
 **Jens Kringelum** Director Genomic Immuno-Oncology **Evaxion Biotech**	**8.00 | 5.00**	**How to Use AI to Solve Bottlenecks in Neo-Epitope Identification** • Important aspects of neo-epitope identification • How improvement in data generation & machine learning helps in identifying relevant neo-epitopes
PolyPeptide GROUP	**8.30 | 5.30**	**Session Details to Be Confirmed**
 **Julia Kodysh** Senior Scientist, Computational Research **Icahn School of Medicine, Mount Sinai**	**9.00 | 6.00**	**Utilizing Novel Computational Techniques to Select Effective & Globally Expressed Neoantigens** • Exploring how best to identify meaningful mutations that will lead to both a T-cell response and a B-cell response and distinguishing irrelevant mutations • Computational and experimental techniques to identify neoantigens that are widely expressed and dispersed throughout disseminated tumor legions • Exploring novel neoantigen sources to drive prediction accuracy
NEC NEC OncoImmunity AS	**9.30 | 6.30**	**Session Details to Be Confirmed**
 **Sari Pesonen** Head R&D **Valo Therapeutics**	**10.00 | 7.00**	**PeptiCRAd, a Platform for Neoantigen Vaccine Delivery in Cancer** • PeptiCRAD is a platform combining oncolytic adenovirus and peptide vaccination in cancer • Peptide antigens are non-covalently/electrostatically attached to the virus surface without compromising OV activity and generate potent cytotoxic CD8+ T cell responses to tumors • PeptiCRAd offers an ideal platform to test novel neoantigens preclinically and in the clinic
L7INFORMATICS	**10.30 | 7.30**	**Session Details to Be Confirmed**
	11.00 | 8.00	**Virtual Speed Networking** Reinventing the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new and lasting connections!
Looking to the Dark Side for Next Generation Neoantigen Discovery		
 **Dolores J. Schendel** CEO & CSO **Medigene AG**	**11.30 | 8.30**	**Dark Matter Antigens: Exploration With Molecular & Cellular Tools** • Solid tumors can display exotic peptides presented by HLA at their cell that are discovered by mass spectrometry and have characteristics of tumor-specific antigens • Molecular tools can be developed to study their broader expression in cancer cell lines and resected cancer specimens • Cellular tools reveal the suitability of these dark matter antigens as targets for immunotherapy

+1 415 735 3289 info@hansonwade.com
www.neo-antigen.com Neoantigens in Immunotherapy

hansonwade

Conference Day One

Wednesday October 27, 2021

8.00 - 18.00 EST | 5.00 - 15.00 PST

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies

Virtual Event

Wendy Hartsock
Director of Scientific Acceleration
CEM

12.00 | 9.00 — **A Simplified Approach to Accelerated Neoantigen Development**

- Streamlined production of neoantigens
- Direct transferability from discovery to production
- Compatibility of green approaches to neoantigen production while maximizing speed and efficiency

Hubert Lam
Senior Director
Genocea Biosciences

12.30 | 9.30 — **Responses to Inhibitory Tumor Antigens, Inhibigens, Suppress Anti-Tumor Immunity & Promote Tumor Growth**

- ATLAS™, Genocea's T cell antigen discovery platform, uniquely identifies surface-presented antigens of anti-tumor T cell responses and antigens of pro-tumor responses (Inhibigens™).
- Inhibigens may be a novel tumor resistance mechanism that generate deleterious, tolerizing immune responses against cancer and should be avoided from vaccines and immunotherapies.
- Inhibigens are found in most cancer patients and the ratio of Inhibigens to neoantigens appears to predict checkpoint inhibitor (CPI) immunotherapy outcomes

Peter Joyce
CEO
Grey Wolf Therapeutics

13.00 | 10.00 — **Targeting ERAP1: Altering Neoantigen Presentation With a Small Molecule**

- Tumor visibility, defined as the level of tumor-specific antigen expression, is shown to strongly correlate with response to checkpoint inhibition and is a vital aspect determining the immunogenicity within the tumor microenvironment
- Grey Wolf have developed inhibitors of ERAP1, an aminopeptidase in the antigen presentation pathway that determines which antigens are presented on the surface of a cell or tumor
- As opposed to developing a vaccine, Grey Wolf ERAP1 small molecule inhibitors alter the immunopeptidome and thus visibility of the tumor, triggering a differentiated T cell response and causing tumor growth inhibition

Ronald Plasterk
Founder, CEO
Frame Cancer Therapeutics

13.30 | 10.30 — **Whole Framome Cancer Vaccination**

- Every tumor analyzed by Whole Genome Sequencing
- Every tumor deep long RNA sequencing
- Identification of all neoantigens resulting from SVs and subsequent RNA splicing

14.00 | 11.00 — **Lunch & Networking**

Using Shared Neoantigens for Development of Off-the-Shelf Immunotherapy

Christelle Johnson
Senior Field Applications Scientist, Cancer Genomics & Immuno-Oncology
Personalis

14.30 | 11.30 — **ImmunoID NeXT: A Comprehensive Platform for Immuno-Oncology – Improving Neoantigen Prediction, Evaluating Tumor Dynamics, and Immunogenomics Profiling**

- Accurate assessment of mutational landscape and putative neoantigens from the analytically-validated exome and transcriptome ImmunoID NeXT platform
- Improved neoantigen presentation and binding predictions through a machine learning algorithm, SHERPA, built upon high quality immunopeptidomics training data from mono-allelic, and multi-allelic samples
- Comprehensive immunogenomics profiling from a single sample to guide neoantigen-based therapies and biomarker discovery

Elisa Scarselli
Co-Founder, CSO
Nouscom

15.00 | 12.00 — **Nouscom Genetic Vaccine Encoding Shared Neoantigens to Treat Tumors with MicroSatellite Instability (MSI)**

- Large neoantigen payload is ensured by Nouscom genetic vaccination platform
- GAd/MVA heterologous prime/boost results in induction of CD8 T cells in preclinical models and cancer patients
- T cells trafficking and expansion in the tumor is the key driver of treatment efficacy

Conference Day One
Wednesday October 27, 2021

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies
Virtual Event

8.00 - 18.00 EST | 5.00 - 15.00 PST

15.30 | 12.30 **New Class of Antigen-Specific Cancer Active Immunotherapies Based on an Off-the-Shelf Antigen Presenting Cell Line (PDC*line)**

Eric Halioua
President & CEO
PDC*line Pharma

- PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
- PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
- The technology can be applied for any cancer

16.00 | 13.00 **Development of Shared Neoantigen Vaccines for Off-the-Shelf Cancer Therapy**

Karin Jooss
Head of R&D
Gristone Bio

- Machine learning prediction of shared neoantigens combined with potent viral vector delivery platforms was applied to the development of a cancer vaccine for the treatment of patients with advanced stage solid tumors
- Clinical and translational data from a Phase 1/2 trial will be presented with learnings applied from "bench to bedside and back to bench" studies to optimize shared neoantigen vaccines

16.30 | 13.30 **Clinical Activity & Immunogenicity of a Neoantigen Immunotherapy in Non-Small Cell Lung Cancer**

Andres Gutierrez
Executive Vice President, CMO
Advaxis Inc

- An off-the-shelf, Listeria based-neoantigen immunotherapy (ADXS-503) has been developed using 22 most prevalent tumor associated antigens in NSCLC
- Dose escalation with monotherapy and in combination with pembrolizumab have been conducted
- A dose expansion cohort using ADXS-503 as an add-on-therapy to pembrolizumab at progression, has shown potential to reverse resistance to the checkpoint inhibitor

17.00 | 14.00 **Afternoon Break & Poster Session**

Engineering T Cells to Optimize Personalized Neoantigen Cell Therapy

17.30 | 14.30 **Identification of Novel pHLA Targets for Solid Tumor Targeting With Cancer Vaccines**

Hans-Peter Gerber
CSO
3T Biosciences

- Advantages of intracellular targets (pHLAs) versus viral, neoantigens or conventional cell surface antigens
- Strategies to find the most prevalent and immunogenic pHLA targets in tumors from CPI responders
- Selection of self-antigen targets with highest tumor vs normal ratios to avoid off-tumor, on-target toxicities

18.00 | 15.00 **Unleashing the Titans: The Gen-011 Neoantigen-Targeted Peripheral T Cell Therapy for Solid Tumors**

Jessica Baker Flechtner
CSO
Genocea Biosciences

- Adoptive T cell therapies have resulted in unprecedented efficacy against solid tumors
- Prioritizing neoantigens with the ATLAS™ bioassay identifies the right targets and avoids pro-tumor Inhibigens™
- The GEN-011 neoantigen-targeted peripheral T cells (NPTs) have broad specificity and are non-exhausted, polyfunctional, cytolytic cells
- The TITAN-1 clinical trial is ongoing (NCT04596033)

18.30 | 15.30 **Chairman's Closing Remarks & Close of Day 1**

Conference Day Two

Thursday October 28, 2021

9.00 - 17.45 EST | 6.00 - 14.45 PST

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies

Virtual Event

9.00 | 6.00 **Coffee & Networking**

Christopher Gallen
Chairman and CEO
Treos Bio Ltd

9.15 | 6.15 **Chairman's Opening Remarks**

Keynote Clinical Case Studies

Andrew Allen
CEO
Gritstone Bio

9.30 | 9.30 **Now It Gets Real- Clinical Data in Advanced Cancer Patients Treated With an Individualized Neoantigen Vaccine**

- Neoantigen-directed immunotherapy has been developed using high quality machine learning-enabled prediction of neoantigens plus viral vector-based delivery of select individualized neoantigens to patients with advanced solid tumors
- A phase 1/2 trial has been conducted in the US/Australia to assess safety, immunogenicity and efficacy of this approach
- Clinical data with up to a year of follow-up, with a focus on colorectal cancer, will be presented

Christopher Gallen
Chairman and CEO
Treos Bio Ltd

10.00 | 7.00 **Treos' Novel & Potentially Transformative Big Data Approach to Increasing the Effectiveness of Cancer Vaccines by Incorporating a Systematic Understanding of Antigen Targets & HLA Responses**

- Treos' approach to producing two families of off-the-shelf personalized cancer vaccines
- Clinical data supporting the utility of the Treos approach
- A systematic approach to creating the future of cancer vaccines

Niranjan Sardesai
President & CEO,
Founder
Geneos Therapeutics

10.30 | 7.30 **Personalized Cancer Vaccine for Treating Patients With Advanced Hepatocellular Cancer**

- GT-EPIC™ DNA plasmid product designed and manufactured for each patient based on their tumor specific neoantigens
- Discuss the interim clinical safety and efficacy data from the first 10 patients treated on study
- The use of immuno-monitoring to assess the potency of the personalized cancer vaccine and mechanism of action of the targeted neoantigens in the clinic.

11.00 | 8.00 **Industry Leader's Fireside Chat**

An executive panel discussion from the C-level leaders of the field to set the scene on neoantigen based therapy development.

Andrew Allen
CEO
Gritstone Bio

Christopher Gallen
Chairman and CEO
Treos Bio Ltd

Niranjan Sardesai
President & CEO, Founder
Geneos Therapeutics

11.30 | 8.30 **Morning Break & Group Networking**

Reimagining Clinical Trial Design to Show True Efficacy of Neoantigen Therapy

Heinz Lubenau
CEO & Co-Founder
Vaximm

12.00 | 9.00 **Optimizing Patient Selection & Stratification to Improve Success in Clinical Trials**

- What should the patient cohort selection look like to give best chance of success?
- Which clinical end points to be selected to assess anti-tumor efficacy?
- How can the late stage product manufacturing process look like for neoantigen programs?

Conference Day Two

Thursday October 28, 2021

9.00 - 17.45 EST | 6.00 - 14.45 PST

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies

Virtual Event

Philip M Arlen
President & CEO
Precision Biologics, Inc

12.30 | 9.30 **Developing mab Therapies From Tumor Neoantigens**

- Monoclonal abs from Tumor antigens were charactered for specificity and antitumor function
- Identity of neo-epitopes were characterized
- Antibody functions were characterized for clinical trial development

cytiva

13.00 | 10.00 **Session Details to Be Confirmed**

13.30 | 10.30 **Lunch & Networking**

Establishing an Adjuvant Approach for Greater Clinical Outcomes

14.00 | 11.00 The Adjuvant Part of Neoantigen Cancer Vaccines: No Clear Winner Has Yet Emerged

- Exploring the use of a cell-based, allogeneic, immune primer for recruitment and activation of cross-presenting DCs
- Harnessing skin-resident memory CD8+ T cells for adaptive immune responses

Alex Karlsson-Parra, CSO, **Immunicum**

14.30 | 11.30 Overcoming Challenges for Effective Cancer Vaccine Therapy

- Improving vaccine activity by combining with RNA encoded cytokines
- Novel treatments to overcome immune escape via MHC I loss

Mathias Vormehr, Director Cancer Vaccines, **BioNTech SE**

15.00 | 12.00 Panel Discussion: Exploring the Best-in-Class Adjuvant to Improve Patient Response to Neoantigen Therapy

- Discussing the best approach to turn the 'cold tumor' into a 'hot tumor'.
- Outlining the variety of neoadjuvant methods to prime immune responses to neoantigen vaccination
- Exploring the potential of a mRNA adjuvant if an mRNA vaccine platform is used for neoantigen delivery

Alex Karlsson-Parra, CSO, **Immunicum**

Mathias Vomehr, Director, **Cancer Vaccines, BioNTech**

Addressing Manufacturing Challenges to Decrease Process & Release Times for Neoantigen Therapeutic Development

14.00 | 11.00 Optimizing Release Testing for Faster Turnaround Time to Patients In Critical Need

- Novel and innovative methods to ensure release of safe products in a faster manner
- Implementation of quality controls assays at each scale up step
- Developing more flexible, risk based approach to release testing to allow for conditional release

Albrecht Meichle, VP Regulatory Affairs & CMC, Vaximm

14.30 | 11.30 Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps

- Discussing strategy for producing cancer vaccines on an industrial scale under GMP conditions
- Exploring how companies have handled the low availability of raw materials (DNA vectors/ viral vectors) due to priority of Covid-19 for manufacturers
- Assessing the best strategy to deal with the logistical manufacturing issues that have arisen due to the pandemic
- Providing insight into different bio-manufacturing timelines, clinical readiness and capacity post-pandemic

Niranjan Sardesai, President & CEO, **Founder Geneos Therapeutics**

Eric Halioua, President & CEO, **PDC*line Pharma**

Albrecht Meichle, VP Regulatory Affairs & CMC, **Vaximm**

15.00 | 12.00 oundtable Discussion: Prioritizing Diversity, Equity & Inclusion in the Neoantigen Field

Chip Clark, CEO, **Genocea Biosciences**

Joann Peters, VP Clinical & Business Operations, **Geneos Therapeutics**

+1 415 735 3289 info@hansonwade.com
www.neo-antigen.com Neoantigens in Immunotherapy

hansonwade

Conference Day Two

Thursday October 28, 2021

9.00 - 17.45 EST | 6.00 - 14.45 PST

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies

Virtual Event

15.30 | 12.30 **Afternoon Break**

Looking Outside of Oncology: Examining the Use of Vaccine Platforms in Infectious Disease and Beyond

Paul Higham
CEO
Valo Therapeutics

16.00 | 13.00 **PeptiVAX, a Vaccine Platform for Flexibly Targeting New & Emerging Infectious Disease**

- PeptiVAX is a platform based on peptide antigen coating of non-replicating adenovirus for delivery of peptide vaccination in infectious diseases.
- Costly and time-consuming genetic engineering of new vaccines to emerging infectious diseases is not required
- A pancoronavirus vaccine strategy targeting existing and emerging strains of coronavirus utilizing novel antigens will be described

Agnete Fredriksen
Chief Innovation & Strategy Officer
Vaccibody As

16.30 | 13.30 **Targeting Antigens to Antigen Presenting Cells to Create More Efficacious Vaccines**

- Vaccibody's 3 modular format optimized for induction of rapid, strong and broad immune responses
- Targeting neoantigens to chemokine receptors on APC for induction of strong and broad CD8 T cell responses
- Combinations and applicability within personalized and off-the shelf cancer vaccines and beyond

17.00 | 14.00 **Chairman's Closing Remarks**

17.15 | 14.15 **Close of Summit**

"The relevance of neoantigens in the clinical efficacy of immunotherapy is beyond doubt. However, several fundamental and practical questions remain unanswered and this meeting is an opportunity to discuss these issues with experts of the field."

Alexandre Harari, Group leader, Department of Oncology UNIL CHUV, **Ludwig Institute for Cancer Research, Lausanne**

Our Partners

NEC
NEC OncoImmunity AS

Industry Development Partner:

NEC OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neo-antigens for personalized cancer immunotherapy. NEC OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in clinically actionable timeframe.

www.oncoimmunity.com

PolyPeptide GROUP

Expertise Partner:

The PolyPeptide Group employs approximately 750 staff at sites in Belgium, France, India, Sweden and the USA. The PolyPeptide Group is the world's largest independent contract manufacturer of therapeutic peptides. The privately-held organization manufactures over one third of all approved peptide drug substances and accounts for over 30% of the sales of outsourced peptide therapeutics worldwide. The Group offers its customers an almost unprecedented long-term security of supply with six GMP facilities worldwide and an exclusive focus on pharmaceutical peptide manufacture.

www.polypeptide.com

Personalis

Expertise Partner:

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited.

www.personalis.com

cytiva

Expertise Partner:

Cytiva is a global life sciences leader with more than 8000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows. Cytiva is the first 'idea to injection' biotechnology company, helping biomanufacturers from drug development, through drug substance and now into drug product with its acquisition of Vanrx.

www.vanrx.com

GET INVOLVED

Hugo Billyard
Partnerships Director
Tel: +1 415 735 3289
Email: sponsor@hansonwade.com

Our Partners

Program Partner:

Cayman's Immunology and Cellular Metabolism Services can complement your drug discovery efforts. Our Immunopeptidome Profiling Services enable deep sequencing analysis of MHC associated peptides by LC-MS/ MS, allowing neoantigen identification in cell lines and tumor tissue. Our Cellular Metabolism Services measure the metabolic response of cells to therapeutics under a wide range of customizable in vitro metabolic environments. Cayman's expertise in cell culture, immunoassays, antibodies, and assay development provides a complete solution for your research needs.

www.caymanchem.com

Program Partner:

The Liberty PRIME is the absolute best system available for synthesizing peptides for personalized medicine. The system is cGMP compliant with unmatched purity, speed, and efficiency for peptide production in batch quantities. No other peptide synthesizer even comes close to the PRIME's incredibly fast cycle times, with absolute minimum waste production. CEM Corporation has pioneered the use of microwave technology for peptide production since 2004 and remains the market leader in peptide synthesis instrumentation.

www.cem.com

Exhibitors

ALMAC

GYROS PROTEIN Technologies

PEPSCAN
Shaping peptides to perfection

CellCarta
formerly Caprion-HistoGeneX

L7INFORMATICS

vivitide
Science for life

CPC scientific
Peptide Partners. Concept to Commercial.

GET INVOLVED

Hugo Billyard
Partnerships Director
Tel: +1 415 735 3289
Email: sponsor@hansonwade.com

Why Partner?

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies
Virtual Event

The **Neoantigen Based Therapies Summit** is the only dedicated industry led meeting focused on ensuring you can truly supercharge vaccine and cell immunotherapies for solid tumors and beyond.

Partnering with the **Neoantigen Based Therapies Summit** will ensure you capitalize on the market share early, cement your position as an industry leader and support the growth of safe and effective macrophage-directed therapies.

This is your opportunity to:

Maximize the 2:1 balance of live content and targeted online networking to **generate leads** and **build new relationships** with senior-level decision-makers from leading pharma and biotech companies

Secure a branding or speaking opportunity to **demonstrate thought leadership**, **drive brand exposure** and differentiate yourself from competitors

Secure a virtual exhibition booth to **showcase your expertise** and educate the industry on how you can support and streamline their efforts

Embrace the tech to **meet your 2021 commercial objectives** and educate key decision-makers on how your expertise can help the TCR community achieve their full potential and reach patients in need

Delegate Seniority Breakdown



*Attendee breakdown from past Neoantigen series events

Total Breakdown of Audience by Industry



GET INVOLVED

Hugo Billyard
Partnerships Director
Tel: +1 415 735 3289
Email: sponsor@hansonwade.com

An Interactive Online Experience

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies
Virtual Event

The **Neoantigen Based Therapies Summit US 2021** committed to delivering the high-quality insights and industry connections that our customers expect, in a format that is accessible from the comfort of your home or office.

We have created the virtual summit to satisfy the industry's need to share cutting-edge research, learn from your peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.

To effectively facilitate this need to learn and connect, our custom-built virtual event platform will combine best-in-class platforms to deliver a seamless event experience. Accessing the platform is simple, you'll be provided with a unique link in the run up to the event that will take you directly to the online event space where you'll follow a few simple steps to set up your delegate profile and get started.

Key Features & Functionalities:

Delegate Profile
Set up personalized profiles to easily identify the name, job title & company of other attendees

Stage Area
Most presentations will be delivered in the 'Stage' area, much like the main conference room onsite

Sessions Area
Smaller groups can get together in this breakout area for panel discussions and other interactive sessions

Demo Area
Visit the virtual exhibition area to explore the solutions our specialist vendors have on offer

Chat Rooms
Connect with your peers and start conversations with individuals or all attendees in private and public chatrooms

Speed Networking
This virtual networking session will connect you with other attendees to establish new industry contacts

What You Can Expect from a Digital Event:

Live Q&As with Speakers
Ask your burning questions directly to our expert speakers in real-time, just as you would at a physical conference

Audience Discussions
Join smaller, informal group chats or video calls designed to spark crucial conversations around key challenges for the industry

2+ Hours of Networking
Facilitated and informal networking breaks will allow you to connect 1-2-1 with other attendees and kick start critical discussions

Content Available Post-Event
On conclusion of the event, presentations will be made available to attendees where possible

If you have any other questions about the platform, please **get in touch**

+1 415 735 3289 info@hansonwade.com
www.neo-antigen.com Neoantigens in Immunotherapy
hansonwade

Ready to Register?

Neoantigen Based Therapies Summit
Weaponizing Vaccine and Cell Based Immunotherapies
Virtual Event

3 Easy Ways To Book

www.neo-antigen.com/take-part/register/

Tel: +1 415 735 3289

Email: register@hansonwade.com

1. Gain the tools and insight you need to maximize the potential of your neoantigen therapeutic and advance your clinical pipeline
2. Gain an in-depth breakdown of the clinical landscape and technology innovations to advance your pipeline to successfully weaponize neoantigens for antitumor treatment
3. Develop long lasting connections with key senior industry leaders to accelerate the clinical and commercial development of your neoantigen based immunotherapies

Secure Your Place Now

Pharma & Biotech	Register & Pay by October 26	On the Day Price
Conference + Bootcamp	$2,797	$2,897
Conference + Workshop Day	$2,797	$2,897
Conference Only	$1,999	$2,099

Standard Pricing (Software & Solution Providers)	Register & Pay by October 26	On the Day Price
Conference + Bootcamp	$3,497	$3,597
Conference + Workshop Day	$3,497	$3,597
Conference Only	$2,499	$2,599

Academic Pricing	Register & Pay by October 26	On the Day Price
Conference + Bootcamp	$2,397	$2,497
Conference + Workshop Day	$2,397	$2,497
Conference Only	$1,799	$1,899

Please note: If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.
All prices shown in USD.

*You must currently be developing drug candidates publicly (evidence on company website required).

Team Discounts*

- **10% discount – 3 Attendees**
- **15% discount – 4 Attendees**
- **20% discount – 5 or more Attendees**

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time.
Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH